ReviewInfection and drug resistance2025
A Comprehensive Analysis of Teicoplanin Population Pharmacokinetic Models in Pediatric Populations: Age-Dependent Variability and Implications for Dose Optimization.
Review in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antibiotic Prophylaxis and Treatment of Neonatal Group B Streptococcus Disease in the Era of Antimicrobial Resistance.Antibiotics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Teicoplanin (TEC) is widely used for treating invasive infections caused by Gram-positive bacteria. Due to its high pharmacokinetic variability, several population pharmacokinetic (PPK) studies have been performed to identify factors contributing to the variability. This review aims to provide a comprehensive overview of published PPK studies and explore potential covariates. Patients and Methods: We systematically searched the PubMed, Web of Science, and Embase databases and compared study characteristics, model parameters, and covariate effects. Visual predictive distributions were used to compare different models. Forest plots and Monte Carlo simulations were used to assess the influence of covariates and probability of target attainment (PTA) against methicillin-resistant Results: A total of eight PPK studies involving preterm infants, neonates, infants, children, and adolescents were finally included. The median weight-normalized clearance (CL) in adolescents was 0.0116 L/h/kg, 14.7% and 16.0% lower than that in infants and children, respectively, and significantly approximately 22.7% lower than that in neonates. Key covariates impacting TEC clearance included body weight, postmenstrual age (PMA), renal function parameters, albumin levels, and continuous kidney replacement therapy (CKRT) status. Monte Carlo simulations indicated that current dosing regimens may be inadequate, particularly when treating MRSA with minimum inhibitory concentration (MIC) = 2 mg/L, as the PTA for AUC Conclusion: TEC dosing in pediatric patients should be individualized, taking into account factors like age, weight, and renal function. Moreover, further population studies are essential to be conducted to clarify the dose-exposure-response relationship of TEC. PROSPERO Registration: CRD420251012884.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.